Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.UMRX · Entity 3793 | President & C.F.O. | March 28, 2018 | March 29, 2018 |
| INCYTE CORPINCY · Entity 3182 | EVP & Chief Financial Officer | July 14, 2025 | July 16, 2025 |
| Keenova Therapeutics plcNONE · Entity 28960 | President and CFO | February 25, 2026 | February 27, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Corp Strategy & Bus Devlp | July 30, 2013 | August 01, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date March 28, 2018 · Filed March 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2025-01-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-03-28 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of the shares vests on January 9, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2025-04-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-03-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 25% of the shares vest on April 30, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.77 · Expires 2027-10-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-03-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: 25% of the shares vest on October 27, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2028-03-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-03-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: 25% of the shares vest on March 28, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vests on January 9, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
F2: 25% of the shares vest on April 30, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
F3: 25% of the shares vest on October 27, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
F4: 25% of the shares vest on March 28, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
INCYTE CORP
Report date July 14, 2025 · Filed July 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,097 |
Reported balance
After 2025-07-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-14 · Tax withholding · Disposed 1,407 · Balance 116,097 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. |
| Common StockSEC Table I · non-derivative | Direct | 114,652 |
Reported balance
After 2025-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-07-15 · Tax withholding · Disposed 1,445 · Balance 114,652 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. |
| Common StockSEC Table I · non-derivative | Direct | 125,759 |
Reported balance
After 2025-07-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-07-15 · Grant · Acquired 11,107 · Balance 125,759 F2: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F3: Including the July 15, 2025 grant, this includes an aggregate of 64,006 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2028-07-15 | Direct | 27,769 |
Reported balance
After 2025-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-15 · Grant · Acquired 27,769 · Balance 27,769 F4: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.25 · Expires 2035-07-14 | Direct | 24,998 |
Reported balance
After 2025-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-15 · Grant · Acquired 24,998 · Balance 24,998 F5: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.
F2: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F3: Including the July 15, 2025 grant, this includes an aggregate of 64,006 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
F4: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
F5: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Keenova Therapeutics plc
Report date February 25, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 174,181 |
Reported balance
After 2026-02-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-25 · Grant · Acquired 101,262 · Balance 174,181 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2: The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.
VERTEX PHARMACEUTICALS INC / MA
Report date July 30, 2013 · Filed August 01, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $83.36 · Expires 2023-07-29 | Direct | 27,500 |
Reported balance
After 2013-07-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2013-07-30 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in 16 quarterly installments from 07/30/2013. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 16 quarterly installments from 07/30/2013.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 50,526 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.92 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 6,816 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.44 · Expires 2028-03-14 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 7,551 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.81 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 6,523 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.36 · Expires 2030-03-05 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 7,322 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.03 · Expires 2031-03-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 5,055 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.28 · Expires 2032-03-10 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 5,293 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.49 · Expires 2033-03-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 4,210 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.32 · Expires 2034-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Disposition to issuer · Disposed 4,536 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F3: For Footnote (3), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: For Footnote (3), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2017 Filed Mar 9, 2017 21:38 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,206 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-011066 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,206 F1 · shares: Represents Restricted Stock Units (RSUs) which vest on the date of the 2018 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 27,500 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-13-038700 · doc4.xml · derivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2023-07-29 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,125 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001209191-13-037018 · doc4.xml · derivative · entry 5 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,125 shares Expires 2020-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/14/2010. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $87.33 | $8,733.00 |
DisclosureSEC source: 0001209191-13-037018 · doc4.xml · nonDerivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,712 F1 · kind: Transaction made pursuant to Ms. Stamoulis' company approved trading plan under Rule 10b5-1. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,025 | $86.25 | $88,406.25 |
DisclosureSEC source: 0001209191-13-037018 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,812 F1 · kind: Transaction made pursuant to Ms. Stamoulis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $86.25 (range $85.96 to $86.55). F3 · price: Ms. Stamoulis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $33.82 | $38,047.50 |
DisclosureSEC source: 0001209191-13-037018 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2013 Filed Jul 9, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 4,687 | $0.00 Strike: $34.57 | $0.00 |
DisclosureSEC source: 0001209191-13-035979 · doc4.xml · derivative · entry 5 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 4,687 shares Expires 2019-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 10/05/2009. Read SEC document |
| July 05, 2013 Filed Jul 9, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,387 | $81.42 | $275,769.54 |
DisclosureSEC source: 0001209191-13-035979 · doc4.xml · nonDerivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,712 F1 · kind: Transaction made pursuant to Ms. Stamoulis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Stamoulis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $81.42 (range $81.01 to $81.77). Read SEC document |
| July 05, 2013 Filed Jul 9, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $80.65 | $104,845.00 |
DisclosureSEC source: 0001209191-13-035979 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,099 F1 · kind: Transaction made pursuant to Ms. Stamoulis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $80.65 (range $80.25 to $80.99). F3 · price: Ms. Stamoulis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2013 Filed Jul 9, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,687 | $34.57 | $162,029.59 |
DisclosureSEC source: 0001209191-13-035979 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2013 Filed May 17, 2013 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $80.50 | $8,050.00 |
DisclosureSEC source: 0001209191-13-027215 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,712 F1 · kind: Transaction made pursuant to Ms. Stamoulis' company approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2013 Filed May 17, 2013 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 502 | $79.48 | $39,898.96 |
DisclosureSEC source: 0001209191-13-027215 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,812 F1 · kind: Transaction made pursuant to Ms. Stamoulis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $79.48 (range $79.27 to $79.79). F3 · price: Ms. Stamoulis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 30, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1 | $0.00 Strike: $34.57 | $0.00 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · derivative · entry 10 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 1 shares Expires 2019-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 10/05/2009. Read SEC document |
| April 30, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1 | $77.88 | $77.88 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · nonDerivative · entry 6 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,712 F1 · kind: Transaction made pursuant to Ms. Stamoulis's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 30, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1 | $34.57 | $34.57 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · nonDerivative · entry 5 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 12,375 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · derivative · entry 9 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 12,375 shares Expires 2020-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document |
| April 29, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 65,624 | $0.00 Strike: $34.57 | $0.00 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · derivative · entry 8 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,376 Underlying: Common Stock · 65,624 shares Expires 2019-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 10/05/2009. Read SEC document |
| April 29, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 57,697 | $79.69 | $4,597,873.93 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · nonDerivative · entry 4 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,712 F1 · kind: Transaction made pursuant to Ms. Stamoulis's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Stamoulis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $79.69 (range $79.35 to $80.29). Read SEC document |
| April 29, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 25,302 | $79.08 | $2,000,882.16 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · nonDerivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,409 F1 · kind: Transaction made pursuant to Ms. Stamoulis's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $79.08 (range $78.36 to $79.34). F3 · price: Ms. Stamoulis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 29, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,375 | $33.82 | $418,522.50 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2013 Filed May 1, 2013 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 65,624 | $34.57 | $2,268,621.68 |
DisclosureSEC source: 0001209191-13-023348 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 45,750 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007136 · doc4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-13-007136 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,712 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| July 25, 2012 Filed Jul 26, 2012 20:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 30,500 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-12-039167 · doc4.xml · derivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2022-07-24 F1 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 10/25/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007783 · doc4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007783 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,708 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-11-039520 · doc4.xml · derivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2021-07-12 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/13/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 58,250 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000016 · edgar.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,250 Underlying: Common Stock · 58,250 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000016 · edgar.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,813 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.